Amendment ID: S3178-509
Amendment 509
Innovations in Veteran Healthcare
Ms. Friedman and Messrs. Collins and Rush move that the proposed new text be amended by adding the following section:-
SECTION ___. Chapter 111 of the General Laws is hereby amended by inserting after section 2K the following section:-
Section 2L. (a) As used in this section the following words shall, unless the context clearly requires otherwise, have the following meanings:
“Bona fide healthcare professional-patient relationship”, a relationship between a registered healthcare professional, acting in the usual course of his or her professional practice, and a patient in which the healthcare professional has conducted a clinical visit, completed and documented a full assessment of the patient's medical history and current medical condition, has explained the potential benefits and risks of medical use of naturally occurring psychedelic materials, and has a role in the ongoing care and treatment of the patient.
“Cultivation registration”, a registration issued to a medical naturally occurring psychedelic materials treatment center to grow medical use naturally occurring psychedelic materials under the terms of this chapter.
“Department”, shall mean the department of public health.
“Healthcare professional”, a duly Massachusetts licensed physician, physician assistant or certified nurse practitioner authorized by the department to issue written certifications.
“Locked area”, a closet, room, greenhouse or other indoor or outdoor area equipped with locks or other security devices, accessible only to registered and authorized pilot participant employees, registered qualifying patients or registered personal caregivers.
“Naturally occurring psychedelic materials”, psilocybin or psilocin and products manufactured or derived therefrom.
“Medical naturally occurring psychedelic materials treatment center”, a pilot participant that has been issued a cultivation registration by the department to cultivate, process or produce naturally occurring psychedelic materials for use in the pilot program and is authorized by the department to sell, distribute, dispense or administer naturally occurring psychedelic materials for the benefit of registered qualifying patients in the treatment of debilitating medical conditions or the symptoms thereof.
“Medical use of naturally occurring psychedelic materials”, the acquisition, cultivation, possession, processing, including development of related products such as food, tinctures, aerosols, oils or ointments, transfer, transportation, sale, distribution, dispensing or administration of naturally occurring psychedelic materials for the benefit of registered qualifying patients in the treatment of debilitating medical conditions or the symptoms thereof.
“Pilot participant”, entities registered with and authorized by the department to administer naturally occurring psychedelic materials in a monitored setting to clinically appropriate patients.
“Psychedelic peer support specialist”, an individual who has received a certification approved by the department to provide non-clinical support services during the preparation, administration and integration phases of psychedelic-assisted therapy under this chapter, and who provides such support under the direct supervision of a healthcare professional. To be eligible for certification, an individual shall have personal lived experience as a recipient of psychedelic-assisted therapy or a substantially similar treatment modality, in addition to any training, education or competency requirements established by the department.
“Qualifying patient”, a person who has been diagnosed by a registered healthcare professional as having a medical condition which would benefit by treatment with naturally occurring psychedelic materials.
(b) There shall be established and set up on the books of the commonwealth a separate fund to be known as the Medical Psychedelics Fund to assist residents of the commonwealth in paying all or part of any costs associated with accessing medical naturally occurring psychedelic materials from an approved pilot participant. Said fund shall consist of all revenues received by the commonwealth from public and private sources as gifts, grants, and donations to further such use of naturally occurring psychedelic materials. The commissioner shall administer the fund in accordance with this section. Amounts credited to the fund shall not be subject to further appropriation. Money remaining in the fund at the end of a fiscal year shall not revert to the General Fund and shall be available for expenditure in subsequent fiscal years. Annually, not later than January 1, the commissioner shall report on the activities of the fund to the clerks of the house of representatives and the senate and to the chairs of the house and senate committees on ways and means. The report shall include: (i) an accounting of money received by the fund broken down by funding source; (ii) a description of the use of funds for the purpose of the administration of naturally occurring psychedelic materials; (iii) an accounting of money expended from the fund broken down by recipient; and (iv) the amount of any unexpended balance.
(c) There shall be appropriation to the department for the purpose of establishing and operating a pilot program to allow for the monitored mental health care of clinically appropriate patients using naturally occurring psychedelic materials as defined by the department for on-site administration by a multi-disciplinary care team in a supervised clinical setting. The department shall issue pilot program permits to not more than 7 facilities to participate in the pilot program for the purposes of establishing the best and safest clinical practices for psychedelic mental health treatment programs in the commonwealth and for the purposes of collecting patient outcomes data regarding the benefits of psychedelic pharmacotherapy. Eligible pilot participant organizations shall exclusively focus operations and treatment on healthcare and shall not be subsidiaries, affiliates or members of cannabis industry organizations, psychedelic molecule development companies, pharmaceutical companies, private equity firms, venture capital firms or other institutional investment entities; provided, no such organizations shall be owned, controlled or held as a portfolio company, in whole or in part, by any private equity firm, venture capital firm or other institutional investment entity.
(d) The department shall promulgate rules and regulations necessary for the operation of a supervised psychedelic pilot in a clinical setting. The department shall establish by regulation all standards and requirements governing the production and cultivation of naturally occurring psychedelic materials necessary for the pilot program, including, but not limited to, producer licensing and operations. The fee for pilot participants to establish or maintain and operate a facility under this pilot shall be determined annually by the secretary of administration and finance so as to defray the department’s administrative costs of the pilot program.
(e) Section 2 of chapter 94C, including psilocybin and psilocin as Schedule I controlled substances, shall not apply to the medical use of psilocybin and psilocin as provided under the pilot program and regulations promulgated hereunder. A licensed facility, designated participant, licensed clinical staff member or patient acting in compliance with the pilot program and regulations promulgated hereunder shall not be subject to arrest, prosecution or civil or professional penalty under state law for activities expressly authorized under the pilot program. A licensed health care practitioner shall not be subject to professional discipline or loss of licensure solely for issuing a written certification under the pilot program, recommending participation in the program to a patient or providing medical services authorized under the program.
(f) The department shall coordinate with research institutions, as it deems appropriate, to facilitate, expand and expedite federally-authorized research on psychedelic-assisted therapies, including, but not limited to, psilocybin, ibogaine, 5-methoxy-n,n-dimethyltryptamine, and 3,4-methylenedioxymethamphetamine, in the commonwealth, including efforts to pursue federal approvals and available state and federal funding in compliance with applicable federal regulations.
(g) All pilot participants shall track patient care outcomes data related to the identification, diagnosis and psychedelic treatment of depression, anxiety, post-traumatic stress disorder and substance use disorder. These data sets shall be reported to the department of public health in a manner specified by the department to assist in the refinement of best clinical protocols and final regulatory frameworks for the safe use of psychedelic material in the commonwealth. The reported data is confidential and is not admissible in court except for gross negligence.
(h) This section shall remain in effect through December 31, 2037, after which it shall be of no further force or effect. The department shall ensure that any licensed producers and designated pilot participants operating under the pilot are given not less than 6 months' written notice of program expiration.
(i) In reviewing and approving applications by entities seeking to become a pilot participant, the department shall make best efforts to approve locations in geographically diverse locations across the commonwealth.